The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).
3 Primary · 22 Secondary · Reporting Duration: From first dose of study drug until death from any cause (up to approximately 60 months)
Experimental Treatment
181 Total Participants · 12 Treatment Groups
Primary Treatment: Hepatocellular Carcinoma (HCC) Part · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: